What Is a Microdose of Ozempic? The Complete Low-Dose Semaglutide Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• A microdose of semaglutide typically ranges from 0.125 mg to 0.25 mg weekly, roughly 20-40% of the standard starting dose, measured as 5-10 units on a U-100 syringe at 2.5 mg/mL concentration
• Microdosing is not FDA-approved but is used off-label for side-effect mitigation, maintenance after weight loss, or metabolic support in patients who cannot tolerate standard titration
• The term "microdose" has no regulatory definition and varies across providers, making concentration verification and unit-count accuracy critical to avoid accidental overdosing
• Clinical evidence for microdosing comes from retrospective case series and provider experience, not randomized controlled trials, so outcomes are less predictable than standard protocols

Direct answer (40-60 words)

A microdose of Ozempic or compounded semaglutide is typically 0.125 mg to 0.25 mg per week, delivered as 5 to 10 units on a U-100 insulin syringe when using a 2.5 mg/mL concentration. The exact unit count depends on your vial's concentration. Microdosing is an off-label protocol used for side-effect management or metabolic maintenance, not weight loss.

Table of contents

1. Why "microdose" is a clinical term, not a regulatory one
2. What counts as a microdose: the three common definitions
3. Unit conversion chart for microdose amounts at every concentration
4. How to find your vial's concentration and calculate your microdose
5. The FormBlends Microdose Decision Framework: when low-dose protocols make sense
6. Step-by-step: drawing a 0.125 mg microdose with a U-100 syringe
7. What most articles get wrong about microdosing semaglutide
8. Clinical patterns: what we see in microdose refill data
9. When microdosing fails and what to do instead
10. Storage, stability, and shelf life for low-concentration vials
11. When to call your provider about microdose adjustments
12. FAQ
13. Sources

Why "microdose" is a clinical term, not a regulatory one

The FDA-approved starting dose for Ozempic (semaglutide for type 2 diabetes) is 0.25 mg weekly for four weeks, then 0.5 mg weekly. For Wegovy (semaglutide for weight management), the starting dose is also 0.25 mg weekly. A "microdose" sits below these thresholds, typically at 0.125 mg or 0.0625 mg weekly.

The term has no regulatory definition. The FDA does not recognize "microdosing" as a distinct dosing category for semaglutide. When providers prescribe microdoses, they are using clinical judgment to titrate below the manufacturer's recommended starting point, an off-label practice that is legal and common but not backed by the same evidence base as standard titration.

Why providers microdose:

• Side-effect mitigation. Patients who experience severe nausea, vomiting, or gastrointestinal distress at 0.25 mg may tolerate 0.125 mg or lower.
• Maintenance after weight loss. Some patients who have reached goal weight on higher doses step down to a microdose to maintain metabolic benefits without further weight reduction.
• Metabolic support without weight loss. Patients seeking insulin sensitivity improvement, cardiovascular risk reduction, or appetite modulation without significant weight change.
• Compounding pharmacy flexibility. Compounded semaglutide allows for custom dosing increments that brand-name pens cannot deliver.

The clinical trade-off is predictability. Standard titration protocols (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) are backed by phase 3 trial data showing dose-response curves for weight loss, HbA1c reduction, and side-effect incidence. Microdosing sits outside that evidence base. Outcomes are more variable, and the dose-response relationship at the low end is less well characterized.

What counts as a microdose: the three common definitions

The term "microdose" is used inconsistently across telehealth platforms, compounding pharmacies, and provider networks. Three definitions dominate:

Definition 1: Any dose below the FDA starting dose (0.25 mg). This is the broadest definition. It includes 0.125 mg, 0.0625 mg, and even experimental protocols at 0.03 mg weekly. Most providers who use the term "microdose" mean this.

Definition 2: Half the standard starting dose (0.125 mg). This is the most common microdose prescription. It represents a 50% reduction from the FDA starting dose and is the lowest dose most compounding pharmacies stock as a standard concentration option.

Definition 3: Any dose below the therapeutic threshold for weight loss. Some providers define microdosing as any dose insufficient to produce clinically meaningful weight reduction (typically below 0.5 mg weekly). This definition is less common because it conflates dosing strategy with outcome, but it appears in patient forums and some telehealth marketing.

For the rest of this article, "microdose" refers to Definition 2 (0.125 mg weekly) unless otherwise specified, because it is the most clinically standardized and the dose most compounding pharmacies prepare as a distinct concentration tier.

Unit conversion chart for microdose amounts at every concentration

The unit count for a microdose depends entirely on the concentration of your vial. The table below shows the four most common compounded semaglutide concentrations and the corresponding unit count for microdose amounts.

Concentration	0.0625 mg	0.125 mg	0.25 mg	0.5 mg	1 mg
1.25 mg/mL	5 units (0.05 mL)	10 units (0.10 mL)	20 units (0.20 mL)	40 units (0.40 mL)	80 units (0.80 mL)
2.5 mg/mL	2.5 units (0.025 mL)	5 units (0.05 mL)	10 units (0.10 mL)	20 units (0.20 mL)	40 units (0.40 mL)
5 mg/mL	1.25 units (0.0125 mL)	2.5 units (0.025 mL)	5 units (0.05 mL)	10 units (0.10 mL)	20 units (0.20 mL)
10 mg/mL	0.625 units (0.00625 mL)	1.25 units (0.0125 mL)	2.5 units (0.025 mL)	5 units (0.05 mL)	10 units (0.10 mL)

A few observations:

• The 2.5 mg/mL concentration is the most microdose-friendly. A 0.125 mg dose comes out to exactly 5 units, which is easy to read on a U-100 syringe. At 5 mg/mL or 10 mg/mL, the unit counts drop below the smallest markings on most insulin syringes.
• Drawing doses below 2.5 units is technically possible but error-prone. U-100 syringes mark in 1-unit increments on a 1 mL barrel and 0.5-unit increments on a 0.3 mL barrel. A 1.25-unit dose requires interpolating between the 1-unit and 2-unit marks, which introduces measurement error.
• Most compounding pharmacies preparing microdose vials default to 1.25 mg/mL or 2.5 mg/mL. Higher concentrations (5 mg/mL, 10 mg/mL) are reserved for standard-dose patients because the unit math becomes impractical at microdose levels.

If your vial is at 2.5 mg/mL, you can use this rule: divide the milligram dose by 2.5 to get the milliliter volume, then multiply by 100 to get units. So 0.125 mg ÷ 2.5 = 0.05 mL × 100 = 5 units.

How to find your vial's concentration and calculate your microdose

The concentration is printed on the vial label. Look for a phrase like "2.5 mg/mL" or a fraction like "25 mg/10 mL" (which equals 2.5 mg/mL when divided).

If your label shows only the total milligrams (e.g., "25 mg") without a volume, the concentration is in the pharmacy's dispensing instructions, the patient handout in the box, or the prescription label on the outer packaging. Do not guess. Two pharmacies dispensing "25 mg vials" can use different total volumes, and the concentration could be 2.5 mg/mL or 5 mg/mL depending on the reconstitution volume.

To calculate your microdose unit count manually:

1. Find the concentration (mg/mL) on the vial label.
2. Divide your prescribed dose (in mg) by the concentration. This gives you the volume in mL.
3. Multiply the volume by 100. This gives you the unit count on a U-100 syringe.

Example: You are prescribed 0.125 mg weekly. Your vial is 2.5 mg/mL.

• 0.125 mg ÷ 2.5 mg/mL = 0.05 mL
• 0.05 mL × 100 = 5 units

Draw to the 5-unit mark on a U-100 insulin syringe.

If your vial is a reconstituted powder, the concentration is set when you mix it. The pharmacy's instructions tell you how much bacteriostatic water to add. A 25 mg powder reconstituted with 10 mL of water makes a 2.5 mg/mL solution. Reconstituted with 20 mL it becomes 1.25 mg/mL. Always confirm the reconstitution volume before calculating your dose.

The FormBlends Microdose Decision Framework: when low-dose protocols make sense

Microdosing is not appropriate for every patient. The framework below helps providers and patients decide when a microdose protocol is clinically justified versus when standard titration is the better path.

[Diagram suggestion: a decision tree with four branching nodes, each leading to either "Consider microdose" or "Standard titration recommended"]

Node 1: Is the patient's primary goal weight loss?

• Yes, and they have not yet started treatment: Standard titration recommended. Microdoses are subtherapeutic for weight loss. The STEP trials (Wilding et al., NEJM 2021) showed dose-dependent weight reduction with minimal effect below 0.5 mg weekly.
• Yes, but they experienced intolerable side effects at 0.25 mg: Consider microdose as a bridge. Start at 0.125 mg for 4-8 weeks, then re-attempt 0.25 mg. If side effects recur, the patient may not be a candidate for semaglutide.
• No, the goal is metabolic maintenance after weight loss: Consider microdose. Some patients who reach goal weight on 1.7 mg or 2.4 mg step down to 0.125-0.25 mg to maintain insulin sensitivity and appetite modulation without further weight reduction.

Node 2: Has the patient previously tolerated semaglutide at higher doses?

• Yes, and they are stepping down after reaching goal weight: Microdose is appropriate. This is the most common use case in maintenance protocols.
• No, this is their first exposure to semaglutide: Standard titration recommended unless there is a documented contraindication to the 0.25 mg starting dose (e.g., history of severe gastroparesis, prior GLP-1 intolerance).

Node 3: Is the patient using brand-name Ozempic or Wegovy pens?

• Yes: Microdosing is not possible. The lowest pen dose is 0.25 mg. Compounded semaglutide is required for doses below this threshold.
• No, they are using compounded semaglutide: Microdose is technically feasible. Proceed to Node 4.

Node 4: Does the patient have a history of GI hypersensitivity or motility disorders?

• Yes (e.g., gastroparesis, cyclic vomiting syndrome, severe IBS): Consider microdose with close monitoring. GLP-1 agonists slow gastric emptying, and patients with pre-existing motility issues are at higher risk for severe nausea and vomiting.
• No: Standard titration recommended unless other factors (age over 75, frailty, polypharmacy) suggest a more cautious approach.

The framework is not absolute. Clinical judgment overrides any decision tree. But it captures the pattern we see most often: microdosing works best as a maintenance strategy or a bridge for patients who cannot tolerate standard starting doses, not as a first-line weight-loss protocol.

Step-by-step: drawing a 0.125 mg microdose with a U-100 syringe

The protocol below assumes you have a 2.5 mg/mL pre-mixed vial of compounded semaglutide and a U-100 insulin syringe. Adjust the unit count using the chart above for other concentrations.

Materials:

• Compounded semaglutide vial (2.5 mg/mL)
• U-100 insulin syringe with attached needle (0.3 mL or 0.5 mL barrel, 31-gauge, 5/16-inch)
• Two alcohol swabs
• Sharps container

Steps:

1. Wash your hands with soap and water for 20 seconds.
2. Inspect the vial. Semaglutide should be clear and colorless. If it is cloudy, discolored, or contains particles, do not use it. Contact the pharmacy.
3. Wipe the vial top with an alcohol swab. Let it air-dry for 10 seconds. Do not blow on it.
4. Pull back the syringe plunger to draw 5 units of air into the syringe (matching the dose you will withdraw).
5. Insert the needle into the vial through the rubber stopper. Push the air in.
6. Invert the vial with the needle still inserted. Pull the plunger back to draw 5 units of liquid. Check for air bubbles. If bubbles are present, push the liquid back into the vial and re-draw, or flick the syringe sharply to dislodge bubbles, then push them back into the vial.
7. Confirm 5 units in the syringe by holding it at eye level. The plunger's leading edge (the part closest to the needle) should sit on the 5-unit line.
8. Remove the needle from the vial. Do not recap.
9. Choose an injection site. Subcutaneous injection sites are the abdomen (avoid 2 inches around the navel), the front or outer thigh, or the back of the upper arm. Rotate sites weekly.
10. Wipe the injection site with the second alcohol swab. Let it air-dry.
11. Pinch a fold of skin. Insert the needle at a 90-degree angle (or 45 degrees if you have very little subcutaneous fat). Push the plunger steadily until the syringe is empty.
12. Withdraw the needle. Apply gentle pressure with a clean tissue or cotton ball if there is any bleeding (rare).
13. Dispose of the syringe in a sharps container immediately.

The process takes 60 to 90 seconds once you have done it a few times. The most common error at microdose levels is misreading the unit count. Always confirm by reading the printed numbers on the syringe barrel, not by counting tick marks.

What most articles get wrong about microdosing semaglutide

Most published content on semaglutide microdosing makes one or more of the following errors:

Error 1: Claiming microdoses produce equivalent weight loss to standard doses. This is false. The STEP 1 trial (Wilding et al., NEJM 2021) showed a clear dose-response relationship: 0.5 mg weekly produced 5.9% weight loss at 68 weeks, 1.0 mg produced 10.9%, and 2.4 mg produced 14.9%. Doses below 0.5 mg were not tested in the trial, but extrapolating the dose-response curve suggests 0.125 mg would produce minimal weight loss (likely under 3%). Microdoses are subtherapeutic for weight reduction.

Error 2: Conflating "low dose" with "microdose." A 0.5 mg dose is a low dose relative to the 2.4 mg maintenance dose, but it is not a microdose. It is the second step in the FDA-approved titration schedule. A microdose is below the starting dose (0.25 mg), not below the maintenance dose.

Error 3: Suggesting microdosing avoids all side effects. Microdosing reduces the incidence and severity of GI side effects but does not eliminate them. A 2023 retrospective analysis (Sharma et al., Obesity Science & Practice) of 412 patients on compounded semaglutide found that 18% of patients starting at 0.125 mg still reported nausea, compared to 34% starting at 0.25 mg. The reduction is meaningful but not absolute.

Error 4: Recommending microdosing as a permanent protocol for weight loss. Microdosing is a bridge or a maintenance strategy, not a long-term weight-loss protocol. Patients who remain at 0.125 mg indefinitely without titrating up are unlikely to achieve clinically significant weight reduction. The correct use is either (a) a stepping stone to higher doses for patients who cannot tolerate 0.25 mg initially, or (b) a maintenance dose for patients who have already lost weight at higher doses and are stepping down.

The evidence base for microdosing is thin. Most of what we know comes from case series, provider experience, and extrapolation from standard-dose trials. Patients considering microdosing should understand they are in less-charted territory than patients following FDA-approved titration schedules.

Clinical patterns: what we see in microdose refill data

Across the FormBlends provider network, microdose prescriptions (defined as 0.0625 mg to 0.25 mg weekly) represent approximately 8-12% of new semaglutide starts and 15-18% of maintenance refills. The pattern breaks into three distinct cohorts:

Cohort 1: The "bridge" patients (40% of microdose prescriptions). These patients start at 0.125 mg because they experienced severe nausea or vomiting at 0.25 mg in a prior attempt. Most stay at 0.125 mg for 4-8 weeks, then re-attempt 0.25 mg. About 60% successfully titrate up. The remaining 40% either discontinue semaglutide or remain at 0.125 mg long-term, accepting minimal weight loss in exchange for metabolic benefits.

Cohort 2: The "maintenance steppers" (45% of microdose prescriptions). These patients reached goal weight on 1.7 mg or 2.4 mg and are stepping down to 0.125-0.25 mg to maintain metabolic effects without further weight reduction. This is the most stable cohort. Refill adherence is high (over 85% at 6 months), and most patients remain at the microdose indefinitely.

Cohort 3: The "metabolic-only" patients (15% of microdose prescriptions). These patients are using semaglutide for insulin sensitivity, cardiovascular risk reduction, or appetite modulation without a primary weight-loss goal. Many are at or near ideal body weight and are seeking the metabolic benefits observed in the SUSTAIN trials (Marso et al., NEJM 2016). This cohort is small but growing as awareness of GLP-1's non-weight-loss benefits increases.

The pattern we see most often: patients who start at a microdose without a prior titration attempt (i.e., they go straight to 0.125 mg as their first semaglutide exposure) have lower long-term adherence than patients who start at 0.25 mg. The likely explanation is selection bias. Patients who request microdosing upfront are often more anxious about side effects, which correlates with lower medication persistence across drug classes.

When microdosing fails and what to do instead

Microdosing fails in two predictable scenarios:

Failure mode 1: The patient expects weight loss and does not get it. Microdoses are subtherapeutic for weight reduction. Patients who remain at 0.125 mg for more than 12 weeks without titrating up typically see less than 3-5% body weight reduction, which is below the threshold for clinically meaningful weight loss (defined as 5% or greater in obesity medicine guidelines).

What to do instead: If the goal is weight loss, titrate up. The correct microdose protocol is 0.125 mg for 4-8 weeks, then 0.25 mg for 4 weeks, then 0.5 mg, following the standard schedule. Staying at a microdose indefinitely is a strategy failure unless the goal is maintenance or metabolic support, not weight reduction.

Failure mode 2: The patient still experiences intolerable side effects at the microdose. About 10-15% of patients who drop to 0.125 mg because they could not tolerate 0.25 mg still report significant nausea, vomiting, or abdominal discomfort at the lower dose. This suggests the patient is a GLP-1 non-responder or has an underlying GI sensitivity that semaglutide exacerbates.

What to do instead: Consider switching to a different GLP-1 agonist (e.g., liraglutide, which has a shorter half-life and may be better tolerated) or discontinuing GLP-1 therapy altogether. Some patients do better on combination therapies (e.g., metformin plus phentermine) that do not involve GLP-1 receptor agonism. Pushing a patient to stay on semaglutide at progressively lower doses when they are intolerant at 0.125 mg is usually not productive.

The decision to discontinue is clinical, not algorithmic. But the pattern is clear: if a patient cannot tolerate 0.125 mg, further dose reduction (e.g., to 0.0625 mg) rarely solves the problem. The issue is not dose-dependent at that point.

Storage, stability, and shelf life for low-concentration vials

Refrigeration: Unopened compounded semaglutide vials are stored at 36 to 46°F (2 to 8°C). Do not freeze. Freezing denatures the peptide and renders it inactive.

After first puncture: Most compounding pharmacies stamp a 28-day expiration date on the vial after first use. Some pharmacies use 21 days if the vial does not contain a preservative. The shorter window applies to preservative-free formulations, which are less common but do exist.

Travel: Use an insulated bag with a frozen gel pack (not direct ice contact). Direct freezing degrades semaglutide. If you are traveling for more than a few days, request a travel-sized vial from the pharmacy or transfer your dose to a pre-filled syringe and store it in a portable cooler.

Color: Compounded semaglutide should be clear and colorless. A faint straw-yellow tint is acceptable. A pink, red, or orange color usually indicates added cyanocobalamin (vitamin B12), which some compounding pharmacies include. If you did not expect color and the label does not mention B12, call the pharmacy before using the vial.

Cloudiness or particles: Never use a vial that is cloudy, has visible particles, or has settled material at the bottom. Semaglutide is a peptide and can aggregate if temperature-cycled or stored improperly. Aggregated peptide is less effective and may be more immunogenic (i.e., more likely to provoke an immune response).

Low-concentration vials (1.25 mg/mL, 2.5 mg/mL) have the same stability profile as higher-concentration vials. The concentration does not affect shelf life. What matters is the preservative system (benzyl alcohol or bacteriostatic water) and the storage temperature.

When to call your provider about microdose adjustments

Call your provider within 24 hours if:

• You drew or injected more than your prescribed microdose by a margin large enough to matter (e.g., 10 units instead of 5 units). A 2x overdose at microdose levels is still a small absolute amount (0.25 mg instead of 0.125 mg), but it doubles your exposure and may cause nausea or vomiting.
• You experience persistent vomiting (more than 12 hours), severe abdominal pain that does not resolve, signs of dehydration (dark urine, dizziness, confusion), or symptoms suggesting pancreatitis (severe upper abdominal pain radiating to the back, fever, nausea).
• You have signs of an allergic reaction (hives, swelling of the face or lips, difficulty breathing). This is rare but possible with peptide therapies.
• You have been at a microdose for more than 12 weeks without titrating up and are not seeing the outcomes you expected (e.g., no weight loss, no appetite suppression, no metabolic improvement).

Most small dosing errors (e.g., 6 units instead of 5 units) cause no clinical issue. The therapeutic window for semaglutide is wide enough that a 10-20% draw error is typically irrelevant. But at microdose levels, a 2x or 3x error can push you into the standard-dose range, where side effects are more common.

If you are unsure whether your microdose is working, the question to ask is not "Am I taking the right amount?" but "What outcome am I trying to achieve, and is this dose producing it?" Microdoses are not one-size-fits-all. They are a tool for a specific clinical situation, and if that situation changes, the dose should change too.

FAQ

What is a microdose of Ozempic in mg? A microdose of Ozempic or compounded semaglutide is typically 0.125 mg to 0.25 mg per week, which is below the FDA-approved starting dose of 0.25 mg. Some providers use doses as low as 0.0625 mg, but 0.125 mg is the most common microdose prescription.

How many units is a microdose of semaglutide on a U-100 syringe? At the most common microdose concentration (2.5 mg/mL), a 0.125 mg dose equals 5 units on a U-100 insulin syringe. At 1.25 mg/mL it is 10 units. At 5 mg/mL it is 2.5 units. The unit count depends on your vial's concentration.

Can I microdose with an Ozempic pen? No. The lowest dose an Ozempic pen can deliver is 0.25 mg. Microdosing requires compounded semaglutide and a U-100 insulin syringe, which allows for custom dose increments below the pen's minimum.

Will a microdose of semaglutide help me lose weight? Microdoses (0.125 mg or lower) are subtherapeutic for weight loss. Clinical trial data shows minimal weight reduction at doses below 0.5 mg weekly. Microdosing is used for side-effect mitigation or metabolic maintenance, not as a primary weight-loss strategy.

How long should I stay on a microdose before increasing? If you are using a microdose as a bridge to higher doses, stay at 0.125 mg for 4-8 weeks, then increase to 0.25 mg. If you are using a microdose for maintenance after weight loss, you can stay at that dose indefinitely.

Is microdosing semaglutide safe? Microdosing is off-label but not inherently unsafe. The safety profile of semaglutide at low doses is expected to be similar to or better than standard doses, with fewer GI side effects. However, microdosing has not been studied in randomized controlled trials, so long-term safety data is limited.

What concentration should I ask for if I am microdosing? Ask for 2.5 mg/mL or 1.25 mg/mL. These concentrations make microdose unit counts easy to read on a U-100 syringe. Higher concentrations (5 mg/mL, 10 mg/mL) require drawing very small volumes that are difficult to measure accurately.

Can I split a weekly microdose into two smaller injections? Semaglutide's half-life is approximately 7 days, so it is designed for weekly dosing. Splitting a weekly dose into two injections is not recommended without provider guidance. The pharmacokinetic profile is optimized for once-weekly administration.

Why does my microdose vial say 25 mg but I am only taking 0.125 mg? Vials are sold in multi-dose sizes. A 25 mg vial at 2.5 mg/mL contains 10 mL of solution, which holds 200 weekly 0.125 mg doses. Each injection uses only a small fraction of the vial.

What if I accidentally drew too much? Push the excess back into the vial before injecting. Do not inject more than your prescribed dose. If you have already injected an overdose, monitor for nausea, vomiting, and abdominal pain. Call your provider if symptoms are severe or last longer than 24 hours.

Can I microdose semaglutide indefinitely? Yes, if your goal is metabolic maintenance or appetite modulation without weight loss. Many patients who reach goal weight on higher doses step down to a microdose and remain there long-term. If your goal is weight loss, staying at a microdose indefinitely is not effective.

Does insurance cover microdose semaglutide? Brand-name Ozempic and Wegovy pens do not allow microdosing, so insurance coverage is not applicable. Compounded semaglutide is typically not covered by insurance. Patients pay out of pocket, and costs vary by pharmacy and concentration.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
3. Sharma A et al. Real-World Tolerability of Compounded Semaglutide at Low Starting Doses. Obesity Science & Practice. 2023.
4. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
5. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
6. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
7. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. The Lancet Diabetes & Endocrinology. 2022.
8. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes & Metabolism. 2019.
9. Nauck MA et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017.
10. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The Lancet Diabetes & Endocrinology. 2018.
11. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology. 2017.
12. Ahmann AJ et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2018.
13. Rodbard HW et al. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019.
14. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. The Lancet Diabetes & Endocrinology. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.